FTSE MIB
33.922,16 +40,66 (+0,12%) Dow Jones
37.866,80 +91,42 (+0,24%) Nasdaq
15.336,32 -265,18 (-1,70%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
83,03 +0,30 (+0,36%) Bitcoin EUR
60.229,59 +685,02 (+1,15%)
Immuneering Corporation (IMRX)
| Chiusura precedente | 1,7700 |
| Aperto | 1,7700 |
| Denaro | 1,6700 x 100 |
| Lettera | 1,6900 x 100 |
| Min-Max giorno | 1,6900 - 1,8200 |
| Intervallo di 52 settimane | 1,6900 - 12,2300 |
| Volume | |
| Media Volume | 683.619 |
| Capitalizzazione | 49,489M |
| Beta (5 anni mensile) | -0,89 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,8800 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 13,29 |
GlobeNewswireImmuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference
– Expanded benchmarking of IMM-1-104 as a single agent across more than 190 patient-aligned models in humanized 3D-tumor growth assays demonstrated high sensitivity in a wide range of MAPK-driven tumor types, including models of RAS and RAF mutant melanoma, pancreatic cancer, and lung cancer – IMM-1-104 in combination with gemcitabine or paclitaxel drove enhanced anti-tumor activity in humanized 3D-tumor growth assays across multiple pancreatic cancer models – Strength of preclinical activity da
- GlobeNewswire
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that it will present preclinical data on IMM-1-104, its lead clinical-stage program, and IMM-6-415 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15, 2023 in Boston. Detail
- GlobeNewswire
Immuneering to Present at the Morgan Stanley Healthcare Conference
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the Morgan Stanley Healthcare Conference to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M
